Efficacy and safety of cobimetinib (C) combined with vemurafenib (V) in patients (pts) with BRAFV600 mutation-positive metastatic melanoma: analysis from the 4-year extended follow-up of the phase 3 coBRIM study

被引：23

作者：

Dreno, Brigitte

Ascierto, Paolo Antonio

McArthur, Grant A.

Atkinson, Victoria

Liszkay, Gabriella

Di Giacomo, Anna Maria

Mandala, Mario

Demidov, Lev V.

Stroyakovskiy, Daniil

Thomas, Luc

De la Cruz-Merino, Luis

Dutriaux, Caroline

Garbe, Claus

Rooney, Isabelle Anne

Hsu, Jessie J.

Park, Erica

Ribas, Antoni

Larkin, James M. G.

机构：

[1] CHU Nantes, Dept Dermatol, Nantes, France

[2] Natl Tumour Inst Fdn G Pascal, Naples, Italy

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Univ Melbourne, Melbourne, Vic, Australia

[5] Univ Queensland, Brisbane, Qld, Australia

[6] Natl Inst Oncol, Budapest, Hungary

[7] Univ Hosp Siena, Ctr Immuno Oncol, Siena, Italy

[8] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy

[9] N N Blokhin Russian Canc Res Ctr, Moscow, Russia

[10] Moscow City Oncol Hosp 62, Moscow, Russia

[11] Lyon Univ, Cancerol Inst Lyon Civ Hosp, Canc Res Ctr Lyon, Pierre Benite, France

[12] Hosp Univ Virgen Macarena, Seville, Spain

[13] Bordeaux Hosp, Dermatol & Pediat Dermatol Dept, Bordeaux, France

[14] Eberhard Karls Univ Tubingen, Tubingen, Germany

[15] Genentech Inc, San Francisco, CA USA

[16] Univ Calif Los Angeles, Los Angeles, CA USA

[17] Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[18] Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9522

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9522

引用

页数：2

共 27 条

[21] Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation- positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study [J].

Ascierto, Paolo A. ;

Stroyakovskiy, Daniil ;

Gogas, Helen ;

Robert, Caroline ;

Lewis, Karl ;

Protsenko, Svetlana ;

Pereira, Rodrigo P. ;

Eigentler, Thomas ;

Rutkowski, Piotr ;

Demidov, Lev ;

Zhukova, Natalia ;

Schachter, Jacob ;

Yan, Yibing ;

Caro, Ivor ;

Hertig, Christian ;

Xue, Cloris ;

Kusters, Lieke ;

McArthur, Grant A. ;

Gutzmer, Ralf .

LANCET ONCOLOGY, 2023, 24 (01) :33-44

[22] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study [J].

Dummer, Reinhard ;

Welti, Michele ;

Ramelyte, Egle .

JOURNAL OF TRANSLATIONAL MEDICINE, 2023, 21 (01)

[23] The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study [J].

Reinhard Dummer ;

Michèle Welti ;

Egle Ramelyte .

Journal of Translational Medicine, 21

[24] Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (vol 395, pg 1835, 2020) [J].

Gutzmer, R. ;

Stroyakovskiy, D. ;

Gogas, H. ;

Robert, Caroline ;

Lewis, Karl ;

Protsenko, Svetlana ;

Pereira, Rodrigo P. ;

Eigentler, Thomas ;

Rutkowski, Piotr ;

Demidov, Lev ;

Manikhas, Georgy Moiseevich ;

Yan, Yibing ;

Huang, Kuan-Chieh ;

Uyei, Anne ;

McNally, Virginia ;

McArthur, Grant A. ;

Ascierto, Paolo A. .

LANCET, 2020, 396 (10249) :466-466

[25] Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up [J].

Reiter, Andreas ;

Gotlib, Jason ;

Radia, Deepti H. ;

Alvarez-Twose, Ivan ;

Deininger, Michael W. ;

George, Tracy I. ;

Panse, Jens ;

Pettit, Kristen M. ;

Vannucchi, Alessandro M. ;

Platzbecker, Uwe ;

Hermine, Olivier ;

Elshoury, Amro ;

Livideanu, Christina Bulai ;

Mesa, Ruben ;

Ustun, Celalettin ;

Triggiani, Massimo ;

Dybedal, Ingunn ;

Jurcic, Joseph ;

Zanotti, Roberta ;

Span, Lambert F. ;

Oh, Stephen T. ;

Yacoub, Abdulraheem ;

Hexner, Elizabeth O. ;

Bose, Prithviraj ;

Lee, Stephanie ;

Sperr, Wolfgang R. ;

Griffiths, Elizabeth A. ;

Butler, Matthew ;

Bidollari, Ilda ;

Lin, Hui-Min ;

Rylova, Svetlana ;

Munoz-Gonzalez, Javier I. ;

DeAngelo, Daniel J. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S425-S426

[26] Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma [J].

Robert, C. ;

Karaszewska, B. ;

Schachter, J. ;

Rutkowski, P. ;

Mackiewicz, A. ;

Stroyakovskiy, D. ;

Lichinitser, M. ;

Dummer, R. ;

Grange, F. ;

Mortier, L. ;

Chiarion-Sileni, V. ;

Drucis, K. ;

Krajsova, I. ;

Hauschild, A. ;

Mookerjee, B. ;

Legos, J. ;

Schadendorf, D. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S663-S664

[27] Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) plus trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. [J].

Flaherty, Keith ;

Davies, Michael A. ;

Grob, Jean Jacques ;

Long, Georgina V. ;

Nathan, Paul D. ;

Ribas, Antoni ;

Robert, Caroline ;

Schadendorf, Dirk ;

Frederick, Dennie T. ;

Hammond, Marc R. ;

Jane-Valbuena, Judit ;

Mu, Xinmeng Jasmine ;

Squires, Matthew ;

Jaeger, Savina A. ;

Lane, Stephen R. ;

Mookerjee, Bijoyesh ;

Garraway, Levi A. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 →